Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection

Koichiro Suzuki, Naoaki Shinzawa, Keisuke Ishigaki, Keiji Nakamura, Hiroyuki Abe, Aya Fukui-Miyazaki, Kazuyoshi Ikuta, Yasuhiko Horiguchi

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.

元の言語英語
ページ(範囲)371-379
ページ数9
ジャーナルMICROBIOLOGY and IMMUNOLOGY
61
発行部数9
DOI
出版物ステータス出版済み - 9 1 2017
外部発表Yes

Fingerprint

Bordetella Infections
Bordetella pertussis
Acellular Vaccines
Pertussis Vaccine
Vaccines
Whooping Cough
Antigens
Bacterial Load
Respiratory System
Developing Countries
Immunization
Morbidity
Mortality
Type V Secretion Systems
Incidence
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Virology

これを引用

Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection. / Suzuki, Koichiro; Shinzawa, Naoaki; Ishigaki, Keisuke; Nakamura, Keiji; Abe, Hiroyuki; Fukui-Miyazaki, Aya; Ikuta, Kazuyoshi; Horiguchi, Yasuhiko.

:: MICROBIOLOGY and IMMUNOLOGY, 巻 61, 番号 9, 01.09.2017, p. 371-379.

研究成果: ジャーナルへの寄稿記事

Suzuki, K, Shinzawa, N, Ishigaki, K, Nakamura, K, Abe, H, Fukui-Miyazaki, A, Ikuta, K & Horiguchi, Y 2017, 'Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection', MICROBIOLOGY and IMMUNOLOGY, 巻. 61, 番号 9, pp. 371-379. https://doi.org/10.1111/1348-0421.12504
Suzuki, Koichiro ; Shinzawa, Naoaki ; Ishigaki, Keisuke ; Nakamura, Keiji ; Abe, Hiroyuki ; Fukui-Miyazaki, Aya ; Ikuta, Kazuyoshi ; Horiguchi, Yasuhiko. / Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection. :: MICROBIOLOGY and IMMUNOLOGY. 2017 ; 巻 61, 番号 9. pp. 371-379.
@article{4721778ad5484d129e37a79cee41d5b0,
title = "Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection",
abstract = "Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.",
author = "Koichiro Suzuki and Naoaki Shinzawa and Keisuke Ishigaki and Keiji Nakamura and Hiroyuki Abe and Aya Fukui-Miyazaki and Kazuyoshi Ikuta and Yasuhiko Horiguchi",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/1348-0421.12504",
language = "English",
volume = "61",
pages = "371--379",
journal = "Microbiology and Immunology",
issn = "0385-5600",
publisher = "Center for Academic Publications Japan",
number = "9",

}

TY - JOUR

T1 - Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection

AU - Suzuki, Koichiro

AU - Shinzawa, Naoaki

AU - Ishigaki, Keisuke

AU - Nakamura, Keiji

AU - Abe, Hiroyuki

AU - Fukui-Miyazaki, Aya

AU - Ikuta, Kazuyoshi

AU - Horiguchi, Yasuhiko

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.

AB - Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85029657366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029657366&partnerID=8YFLogxK

U2 - 10.1111/1348-0421.12504

DO - 10.1111/1348-0421.12504

M3 - Article

C2 - 28752940

AN - SCOPUS:85029657366

VL - 61

SP - 371

EP - 379

JO - Microbiology and Immunology

JF - Microbiology and Immunology

SN - 0385-5600

IS - 9

ER -